Enterprise Value to EBITDA Ratio: Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX) revenues rely on the implementation of gene therapy, where the primary catalysts will be the commercialization of REQORSA for lung therapy and the development of diabetes treatments. This chart of market price action based on the EV/EBITDA metric reflects 0.00. High testing costs and unique gene delivery patents create a steep barrier to entry, protecting the niche from players lacking colossal resources.
Analytical breakdowns and data insights for company genprex.com (GNPX)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
GNPX - Final Profit|Projected Future Earnings Genprex, Inc.|GNPX - Market Cap to Earnings|Projected Price to Earnings Genprex, Inc.|GNPX - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Genprex Inc|GNPX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Genprex|GNPX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months genprex.com|GNPX - Earnings per share growth this year|Earnings growth forecast for next year Genprex, Inc.
Initial company analysis:GNPX (Genprex, Inc)
The integration of robotic systems into the gene therapy development of Genprex, Inc. (GNPX) optimizes operating expenses, which directly impacts the formation of EBITDA. The EV/EBITDA ratio on the valuation chart compares the total enterprise value, including debt, with this financial result, allowing investors to assess the real value of assets relative to their ability to generate cash flow.
Competitor analysis for Genprex, Inc.
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|delcath.com (DCTH) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY (Accuray, Inc.) - Enterprise Value to Operating Income Before Depreciation|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ACTU (actuatetherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|FATE - Company Value to EBITDA|Aadi Bioscience - Enterprise Value to EBITDA Ratio|TCRX: Enterprise Value to Operating Income Before Depreciation|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|CVM: EV/EBITDA Multiple|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Enterprise Value to Operating Income Before Depreciation ARTV (Artiva)|EV/EBITDA Multiple ANL|Enterprise Value to EBITDA Ratio Veru Inc VERU|Tempest Tx - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Xilio Therapeutics Inc (XLO)|Enochian BioSciences - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Mural Oncology plc (MURA)|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OKUR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|Curis Corp - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio APLM (Apollomics, Inc.)|tharimmune.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ADVB (Advanced Biomed)|CLDI - Enterprise Value to EBITDA Ratio|Sunshine Biopharma - EV/EBITDA Multiple|XBIO - EV/EBITDA Multiple|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation PPBT|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeiGene Ltd. (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|Business Value to Operating Income Before Depreciation IKNA|NTBL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|Enterprise Value to EBITDA Ratio AAPGV
